19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.

AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.

AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials forthe information on AXEL MARK's entry into the healthcare business.

○Disclosure on 26th March, 2021
https://contents.xjstorage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf

The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the valueof more than $12bn. by 2024. ※“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and homediagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.

In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for moleculardiagnosis, and test kits with various features have been commercialized, and new products will continue to bereleased in the market from now on.

Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas venturesthat do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercializationrights and develop appropriate business partners. We believe that this partnership can build the collaborativevalue chain in the molecular diagnosis market.

Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting thespread of new medical diagnosis technologies.

※Source:”Molecular Diagnostics Market” Datamonitor Healthcare（Published on 30th Sep. 2020）Global Information Inc.
https://www.gii.co.jp/report/dchc967500-molecular-diagnostics-market.html＜Corporate Profile＞■AXEL MARK Inc.
Representative:President & CEO, Hiroshi Matsukawa

Location:1-32-2 Honcho Nakano-ku, Tokyo JapanFounded:March, 1994

Website:https://www.axelmark.co.jp

Business Description:Healthcare, Advertisement, Block chain technology, IoT■Axcelead, Inc.
Representative:President & CEO, Tomoyuki Fujisawa

Location:26-1, Muraoka-Higashi 2-chome Fujisawa, Kanagawa Japan

Established:April, 2020

Website: https://www.axcelead-hd.com

Business Description:Owns shares or interests in companies that operate businesses related topharmaceuticals and medical devices. Support the business activities of the company and contribute toimproving the corporate value of the entire group.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━【Contact】

AXEL MARK Inc. IR division

1-32-2 Honcho Nakano-ku, Tokyo Japanpress@axelmark.co.jp

T E L : 03-5354-3351

Axcelead, Inc. Media Relations division

26-1, Muraoka-Higashi 2-chome Fujisawa, Kanagawa Japan
hd_contact@axcelead.com━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━＃ ＃The name of companies and services in this release are all registerd trademarks ＃ ＃